183 related articles for article (PubMed ID: 14506059)
1. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
[TBL] [Abstract][Full Text] [Related]
2. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
Barchiesi F; Gallo D; Caselli F; Di Francesco LF; Arzeni D; Giacometti A; Scalise G
J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
[TBL] [Abstract][Full Text] [Related]
3. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans.
Nguyen MH; Barchiesi F; McGough DA; Yu VL; Rinaldi MG
Antimicrob Agents Chemother; 1995 Aug; 39(8):1691-5. PubMed ID: 7486902
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
7. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
8. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
[TBL] [Abstract][Full Text] [Related]
9. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
10. Genotypic diversity of Iranian Cryptococcus neoformans using multilocus sequence typing (MLST) and susceptibility to antifungals.
Moslem M; Fatahinia M; Kiasat N; Mahmoudabadi AZ
Mol Biol Rep; 2021 May; 48(5):4201-4208. PubMed ID: 34057687
[TBL] [Abstract][Full Text] [Related]
11. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
13. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of antifungal combination against Cryptococcus neoformans.
Rossato L; Loreto ES; Venturini TP; Azevedo MI; Al-Hatmi AMS; Santurio JM; Alves SH
Diagn Microbiol Infect Dis; 2019 Jun; 94(2):155-156. PubMed ID: 30679056
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
Dannaoui E; Paugam A; Develoux M; Chochillon C; Matheron J; Datry A; Bouges-Michel C; Bonnal C; Dromer F; Bretagne S
Clin Microbiol Infect; 2010 Jul; 16(7):863-9. PubMed ID: 19778296
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. Comparison of broth dilution and semisolid agar dilution for in vitro susceptibility testing of Cryptococcus neoformans.
Del Poeta M; Barchiesi F; Morbiducci V; Arzeni D; Marinucci G; Ancarani F; Scalise G
J Chemother; 1994 Jun; 6(3):173-6. PubMed ID: 7983499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
